Paul Miranda, MD

Board-Certified in Family Medicine · Emergency Physician · Obesity Medicine Association member

I’m an emergency and Family Medicine physician in Chattanooga, Tennessee, and founder of Summit Metabolic Health. I read every patient chart personally. This article reports on a topic patients keep asking about — it is education, not an endorsement.

Medically reviewed by Paul Miranda, MD

If you’re searching “Zepbound Chattanooga,” you’re probably not chasing a brand name. You want the weight loss the data backs up — not a vial from an unregulated website, and not a number on a box. Here’s what most people don’t find out until they call for pricing: Zepbound’s list price runs well above what the drug itself actually requires to work. The active ingredient, tirzepatide, is available right here in Chattanooga through a physician-dosed compounded program, at a fraction of the brand invoice. I’m Dr. Paul Miranda. I’ll walk through what Zepbound is, what the trial data actually showed, and what both paths cost.

Zepbound is Eli Lilly’s brand name for tirzepatide, dosed and marketed specifically for chronic weight management. The same molecule, at different doses, is sold as Mounjaro for type 2 diabetes. Most people searching “Zepbound Chattanooga” aren’t loyal to the brand — they found it through a commercial, a friend, or a headline, and what they actually want is the result: meaningful, sustained weight loss, managed by someone who knows what they’re doing. The brand name is marketing. The molecule is medicine. Those are two different questions, and conflating them is how people end up paying for the first when they only needed the second.

Chattanooga doesn’t have a Lilly storefront or a Zepbound-branded clinic. What it does have is pharmacies that compound tirzepatide to a physician’s prescription, and physicians — including me — who will actually write that prescription after reviewing your history, not after a five-minute intake form decides for you.

Tirzepatide’s data isn’t vague. In SURMOUNT-1 (Jastreboff et al., NEJM, 2022), patients on the 15mg dose lost up to 20.9% of body weight on average over 72 weeks. The extension data goes further: among prediabetic patients with obesity followed for 176 weeks, tirzepatide produced a 94% reduction in progression to type 2 diabetes.

Here’s the mechanism, in plain terms. Semaglutide works on one receptor — GLP-1. Tirzepatide works on two — GLP-1 and GIP. That added GIP agonism improves insulin sensitivity and how fat tissue handles lipids, which is the biological reason tirzepatide outperforms GLP-1-only drugs on weight-loss magnitude. I go deeper on that head-to-head comparison in tirzepatide vs. semaglutide, if you want the full breakdown.

The honest caveat: these are trial averages. They tell you what the drug does in a studied population, not what it will do for you specifically. Nobody can promise you 20.9%. SURMOUNT-1 enrolled adults with obesity or overweight with at least one weight-related condition, dosed over 72 weeks with regular follow-up — the result came from sustained medical supervision, not a vial shipped once and forgotten.

Brand Zepbound’s list price puts it well north of what Summit charges for compounded tirzepatide — our band runs $175-225/month, dosed and adjusted by a physician.

Compare that to the direct-to-consumer telehealth players, since that’s who else shows up in a Zepbound search. Hims exited compounded GLP-1s entirely in March 2026, after its $49-pill pricing scandal. Hims now sells branded-only GLP-1s for roughly $448/month, with no physician chart review — a questionnaire and a script, not a doctor reading your history. Hims is also facing an October 2026 securities-fraud suit alleging near-instant scripting with no clinical oversight, and carries a 2.9 Trustpilot rating across roughly 9,200 reviews. Ro is similarly branded-only, running $349-498/month. Neither has a Chattanooga address or a physician who actually reads your chart. I’ve written about Hims specifically before — see Hims alternatives in Chattanooga for the fuller comparison.

Here’s the honest caveat on the compounded side: compounded tirzepatide is not an FDA-approved finished product. It’s prepared by a licensed pharmacy under state board compounding rules, using the same active molecule as Zepbound — the molecule is identical; the manufacturing pathway is not. That distinction matters, and I’d rather you hear it from me than find out later.

Run the math and the gap is still wide even with that caveat priced in. A year of brand Zepbound at list price costs multiples of a year of Summit’s compounded program — and that’s before counting what Hims or Ro charge for a branded-only script with no chart review attached. The savings aren’t a discount on care. They’re what’s left over once you stop paying for a factory-made box and a national ad budget.

A checkbox form approves a dose. It doesn’t catch the patient whose nausea means the dose needs to come down, or the one who’s losing weight too fast because nobody adjusted anything after the first fill. At Summit, I personally review every chart — not a nurse queue, not software running a script. I work ER shifts, and I see what happens when a GLP-1 gets escalated fast with no one watching: dehydration, gastroparesis, patients who stopped because side effects weren’t managed, not because the drug failed them.

Summit’s approach is slower on purpose. Instead of climbing the manufacturer’s fastest titration schedule, I keep patients at the lowest effective dose as long as possible, targeting a controlled 1-1.5 lb/week loss rather than the fastest number the drug can produce. Every 25 lbs lost, we hold the dose rather than automatically stepping it up. At goal weight, the dose comes down slowly too — a taper to the lowest dose that holds the result, not a cliff where the prescription just stops. That’s a clinical decision, made chart by chart, not a default a DTC script can make for you. I wrote more on why that distinction matters in physician-supervised care vs. the telehealth mill model.

Before you start tirzepatide anywhere, ask three questions. Is my dose being adjusted to how I’m actually tolerating it, or am I just following a fixed schedule? Is a physician reading my chart, or did a questionnaire approve me in minutes? What happens when I hit my goal weight — is there a maintenance plan, or does the subscription just keep running at the same dose indefinitely?

If the answer to any of those is “I don’t know,” that’s worth finding out before the first vial ships.

Two more worth asking. Does the program screen for conditions where tirzepatide isn’t appropriate — a personal or family history of medullary thyroid cancer, for instance, or active gallbladder disease? And can you reach the prescribing physician directly if side effects show up at week two, or does every message route through a support ticket first? A program built around compounded tirzepatide should have straightforward answers to all five. A page that only talks about price usually hasn’t thought about the other four.

Tirzepatide’s results are real and well-documented. What you pay for them, and who’s watching your chart while you take them, shouldn’t be an afterthought. Summit is board-certified, physician-led, and local to Chattanooga — not a nationwide script factory. You can read more on how we approach GLP-1 therapy on the Summit blog.

Ready to start? Apply at summitmetabolichealth.com/apply.

This post is for informational purposes and does not replace an individualized medical evaluation. Tirzepatide carries risks and side effects; a physician should review your history before you start.